Aytu Biopharma (AYTU) Operating Expenses (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Operating Expenses data on file, last reported at $11.7 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $11.7 million, up 12.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.8 million (up 5.53% YoY), and the FY2025 annual result was $53.7 million, up 5.95% from the prior year.
• Operating Expenses grew to $11.7 million in Q1 2026 per AYTU's latest filing, from $11.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $66.1 million in Q1 2022 and troughed at $10.4 million in Q1 2025.
• A 5-year average of $18.8 million and a median of $13.3 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 2179.55% in 2022, then plunged 67.78% in 2023.
• A 5-year view of Operating Expenses shows it stood at $24.2 million in 2022, then slumped by 52.58% to $11.5 million in 2023, then advanced by 8.94% to $12.5 million in 2024, then declined by 7.11% to $11.6 million in 2025, then climbed by 0.6% to $11.7 million in 2026.
• Business Quant data shows AYTU's Operating Expenses at $11.7 million in Q1 2026, $11.6 million in Q4 2025, and $10.7 million in Q3 2025.